Effect of sodium nitroprusside combined with dobutamine in the treatment of coronary atherosclerotic heart disease with heart failure

Objective To investigate the clinical effect of sodium nitroprusside combined with dobutamine in the treatment of coronary atherosclerotic heart disease(CHD)with heart failure, and to evaluate the effect of improving cardiac function. Methods A total of 170 CHD patients with heart failure who were admitted from May 2017 to April 2018 were randomly divided into the sodium nitroprusside treatment group and combined treatment group, with 85 patients in each group.In the sodium nitroprusside treatment group, 45 males and 40 females were aged(64.27±10.61), ranging from 43 to 75 years old.In the combined treatment group, 46 males and 39 females were aged(64.56±10.78)years, ranging from 44 to 75 years.Sodium nitroprusside was used in the treatment group, while dobutamine was used in the combined treatment group.Clinical effect was evaluated, pulmonary artery pressure and cardiac function were evaluated, and hemorheology indexes were detected.Clinical effect was evaluated, and clinical symptom improvement was assessed by Lee′s heart failure score scale.Cardiac output per stroke volume(SV), cardiac output(CO)and left ventricular ejection fraction(LVEF)were assessed by echocardiography, and serum levels of NT-proBNP, CK-MB, hs-CRP and IL-6 were detected. Results The effective rate of combined treatment group[80.0%(68/85)]was higher than that of sodium nitroprusside treatment group[69.4%(59/85)], and the difference was statistically significant(P<0.05). After treatment, Lee′s heart failure score(8.26±0.93)in sodium nitroprusside treatment group was higher than that in combination treatment group(6.07±0.97), (P<0.05). After treatment, SV[(46.13±1.77)ml/ time], LVEF[(54.15±1.39)%], CO[(5.49±0.54)L/min] in the combined treatment group were all higher than that in the sodium nitroprusside treatment group [(43.05±1.73)ml/ time, (49.04±1.56)%, (4.61±0.47)L/min], (P<0.05). After treatment, blood levels of NT-ProBNP[(452.70±102.31)pg/ml], CK-MB [(1.60±0.48)ng/ml], hs-CRP[(21.08±6.04)mg/L], and IL-6[(9.31±1.48)ng/L] in the combined treatment group were lower than those in the sodium nitroprusside treatment group[(609.85±108.73)pg/ml, (2.33±0.41)ng/ml, (26.54±5.18)mg/L, (9.31±1.48)ng/L], (P<0.05). Conclusion Application of sodium nitroprusside combined with dobutamine in the treatment of CHD patients with heart failure, the clinical effect is significant, can reduce the damage of cardiac function, promote the improvement of cardiac function. Key words: Coronary atherosclerotic heart disease; Heart failure; Sodium nitroprusside; Dobutamine; Cardiac function